Exhibit 99.1

Contact:
Incara Pharmaceuticals
W. Bennett Love
919-558-1907

For Immediate Release:

                 Incara Stock Moves to OTC Bulletin Board Market

Research Triangle Park, N.C., September 25, 2002 - Incara Pharmaceuticals
Corporation (OTC Bulletin Board: INCR) today announced that it has been informed
that its common stock does not meet the requirements for continued listing for
the Nasdaq National Market and will begin trading on the OTC Bulletin Board
under its current symbol "INCR." The OTC Bulletin Board(R) (www.otcbb.com) is a
regulated quotation service that displays quotes, last-sale prices, and volume
information in over-the-counter (OTC) equity securities. An OTC equity security
generally is any equity that is not listed or traded on Nasdaq(R) or a national
securities exchange. OTCBB securities include national, regional, and foreign
equity issues, warrants, units, American Depositary Receipts (ADRs), and Direct
Participation Programs (DPPs).

Incara Pharmaceuticals Corporation (www.incara.com) is focused on disease
therapies based on tissue protection, repair and regeneration. The company is
developing a series of catalytic antioxidants as treatments for protection from
damage occurring in cancer radiation therapy and stroke and for protection of
cells in transplantation. Incara has received allowance of an Investigational
New Drug Application (IND) to begin Phase 1 clinical trials of cryopreserved
human liver cells for the treatment of patients with cirrhosis and end-stage
liver disease.

The statements in this press release that are not purely statements of
historical fact are forward-looking statements, and actual results might differ
materially from those anticipated. These statements and other statements made
elsewhere by Incara or its representatives, which are identified or qualified by
words such as "intends," "likely," "will," "suggests," "expects," "might,"
"may," "believe," "could," "should," "would," "anticipates," "plans," or the
negative of those terms or similar expressions, are based on a number of
assumptions that are subject to risks and uncertainties. Important factors that
could cause results to differ include risks associated with the need to obtain
funds for operations and uncertainties of clinical trials, scientific research
and product development activities. These and other important risks are
described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its
registration statements filed with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Incara assumes no obligation
to update the information in this release.